pipeline therapeutics hearing loss treatment

Pipeline Therapeutics Initiates Phase 1/2a Clinical Trial of PIPE-505 to Treat Sensorineural Hearing Loss

SAN DIEGO, CALIFORNIA –Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the initiation of a Phase 1/2a trial of the company’s lead product candidate, PIPE-505, a small molecule gamma secretase inhibitor (GSI), in sensorineural hearing loss (SNHL) associated with hearing speech in noisy environments.…

Read More